SY48 - MASLD 2026 Updates: From Pathophysiology to Integrated Management and Emerging Therapies

Monday, June 15, 2026

10:30 AM - 12:00 PM CT

Location: Room W184ABC

Symposium Chair(s)

Michael Roden, Dr.

Professor
German Diabetes Center
Dusseldorf, GERMANY

Disclosure(s): No financial relationships to disclose
LC

Lisa Chow, MD, MS

Disclosure information not submitted.

Disclosure(s):

Michael Roden, Dr.: No financial relationships to disclose

Metabolic-associated steatotic liver disease (MASLD) lies at the intersection of obesity, insulin resistance, and cardiovascular risk. This session will connect the physiologic and pathophysiologic underpinnings of MASH with strategies for comprehensive metabolic management, emphasizing lifestyle interventions and treatment of associated cardiometabolic disorders. It will also address the therapeutic potential and safety of thyroid hormone receptor agonists as novel agents for hepatic steatosis and fibrosis. Together, these talks provide an integrated view of disease mechanisms, clinical management, and emerging pharmacologic opportunities for improving outcomes in MASH.

Presentations:

10:30 AM - 11:00 AM CT

Thyroid Hormone Receptor Agonists in Steatotic Liver Disease: Effects and Side Effects
Symposium Speaker: Fernando Bril, MD – UNIVERSITY OF ALABAMA AT BIRMINGHAM
11:00 AM - 11:30 AM CT

Integrated Management: Lifestyle, Metabolic Comorbidities, and Cardiovascular Risk
Symposium Speaker: Scott Isaacs, MD (he/him/his) – Emory University School of Medical
11:30 AM - 12:00 PM CT

From Physiology to Pathophysiology of MASH
Symposium Speaker: Mary Rinella